<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01391117</url>
  </required_header>
  <id_info>
    <org_study_id>CR017992</org_study_id>
    <secondary_id>TMC649128HPC1002</secondary_id>
    <nct_id>NCT01391117</nct_id>
    <nct_alias>NCT01532557</nct_alias>
  </id_info>
  <brief_title>TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin</brief_title>
  <official_title>A Phase Ib, Double-Blind, Randomized, Placebo-Controlled Trial in Genotype 1 HCV-Infected Subjects to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Repeated Doses of TMC649128 Given as Monotherapy and Given in Combination With Pegylated Interferon + Ribavirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tibotec BVBA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tibotec BVBA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine in genotype 1 Hepatitis C Virus (HCV)-infected
      participants, the safety, tolerability, pharmacokinetics (how the drug is absorbed in the
      body, how it is distributed within the body and removed from the body over time) and
      antiviral activity of repeated doses of TMC649128 given as monotherapy and given in
      combination with pegylated interferon + ribavirin. We assess the
      pharmacokinetic/pharmacodynamic (how the study medication affects the body) (PK/PD)
      relationship for antiviral activity, active metabolite and safety of TMC649128 and its
      metabolites. We determine the short term safety and tolerability of the co-administration of
      TMC649128 and pegylated interferon + ribavirin during multiple dosing for 14 days in
      treatment-naive genotype 1 HCV-infected participants. We explore the effect of pegylated
      interferon + ribavirin on the pharmacokinetics of TMC649128 during the multiple dosing for 14
      days in treatment-naive genotype 1 HCV-infected participants. We also assess in a preliminary
      way the short term antiviral effect of the combination of TMC649128 with pegylated interferon
      + ribavirin during a 14-day dosing period in treatment-naive genotype 1 HCV-infected
      participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TMC649128 is a nucleoside inhibitor (NI) of hepatitis C virus (HCV) polymerase in development
      for the treatment of chronic hepatitis C infection. Treatment-naive genotype 1 HCV-infected
      participants are participants who have never received (pegylated) interferon ([Peg]IFN),
      ribavirin (RBV) or any other approved or investigational treatment for chronic HCV infection.
      Treatment-experienced genotype 1 HCV-infected participants are defined as previous
      non-responder and relapse subjects to previous treatment regimens (IFN/RBV or PegIFN/RBV),
      who have never received a HCV polymerase inhibitor and HCV protease inhibitor treatment was
      stopped since at least one year. This study is a Phase Ib, double-blind, randomized,
      placebo-controlled trial in genotype 1 HCV-infected participants to determine the safety,
      tolerability, pharmacokinetics and antiviral activity of repeated doses of TMC649128 given as
      monotherapy and given in combination with pegylated interferon + ribavirin. This trial
      consists of 2 phases. In the first phase TMC649128 will be given as monotherapy during 10
      days at different doses and dosing regimens. In the second phase TMC649128 will be
      administered at one selected dose regimen in combination with PegIFN a-2a/RBV for 14 days.;
      All dosages of TMC649128 or placebo are given orally under fed conditions.; The monotherapy
      phase includes 3 panels (panel 1-3) and the combination therapy phase includes 1 panel (panel
      4). In panel 1, subjects are randomly assigned to receive TMC649128 at 1000 mg q24h (every
      24h) (n=8) or placebo (n=2) q24h on Days 1-10. In panel 2 subjects are randomized into Arm 1
      and Arm 2 and within each arm, subjects are randomly assigned to receive TMC649128 or placebo
      as follows: In arm 1 volunteers receive TMC649128 at a selected dose (n=8) or placebo (n=2)
      q12h on Days 1-10. In arm 2 volunteers receive TMC649128 at a selected dose (n=8) or placebo
      (n=2) q24h on Days 1-10. Panel 3: TMC649128 at a selected dose (n=8) or placebo (n=2) q12h
      (every 12h) OR q24h on Days 1-10 where the assignment is determined by randomization; Panel 4
      volunteers are randomized into Arm 1 and Arm 2. In panel 4, arm 1, 10 volunteers receive
      placebo (q12h OR q24h, dosing regimen matched to Arm 2 of Panel 4) + PegIFN a-2a/RBV on Days
      1-14. In Panel 4, arm 2, 10 volunteers receive TMC649128 at a selected dose (q12h OR q24h) +
      PegIFN a-2a/RBV on Days 1-14.; The actual dose of Panel 1 is derived from data obtained from
      the currently ongoing MC649128HPC1001 trial. The actual dose in Panel 2 will depend on the
      results of Panel 1 (total daily dose of TMC649128 administered in both arms of Panel 2 will
      be the same. The dose of TMC649128 of the q24h regimen in Arm 2 will be higher than the q24h
      dose administered in Panel 1 [1000 mg q24h]). The actual doses and dose regimens in Panels 3
      and 4 will depend on the results of Panels 1 and 2 (data review meetings). Selection of doses
      and dose regimens in Panels 2, 3 and 4 will also depend on the data obtained from trial
      TMC649128HPC1001. Dosing will stay within the exposure limits. The intended doses for Panels
      2 and 3 are 2000 mg or 3000 mg q12h or q24h, but may be adapted based on previous clinical
      data. If needed and based on the outcome of the Panel 1 results, subjects in Panel 3 may
      eventually receive a lower dose than in Panel 1. See detailed study description.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Antiviral activity was considered insufficient to warrant further clinical development of
    TMC649128.
  </why_stopped>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the steady-state plasma concentrations of TMC649128.</measure>
    <time_frame>From baseline up to Day 80 per panel (panel 1 + panel 2 + panel 3).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the steady-state plasma concentrations of TMC649128 following co-administration with pegylated interferon + ribavirin.</measure>
    <time_frame>From baseline up to day 84 (panel 4).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral load decreases and/or changes of viral load from baseline (HCV RNA copies/ml) (PK/PD).</measure>
    <time_frame>For monotherapy from baseline up to Day 80 per panel (panel 1 + panel 2 + panel 3) and for combination therapy from baseline up to day 84 (panel 4).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability - TMC649128 as monotherapy and when co-administered with pegylated interferon + ribavirin.</measure>
    <time_frame>For monotherapy from baseline up to Day 80 per panel (panel 1 + panel 2 + panel 3) and for combination therapy from baseline up to day 84 (panel 4).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antiviral activity (HCV RNA levels) of TMC649128 as monotherapy and when co-administered with pegylated interferon + ribavirin.</measure>
    <time_frame>For monotherapy from baseline up to Day 80 per panel (panel 1 + panel 2 + panel 3) and for combination therapy from baseline up to day 84 (panel 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiviral activity (viral breakthrough) of TMC649128 as monotherapy and when co-administered with pegylated interferon + ribavirin.</measure>
    <time_frame>For monotherapy from baseline up to Day 80 per panel (panel 1 + panel 2 + panel 3) and for combination therapy from baseline up to day 84 (panel 4).</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC649128 panel 4 arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128 administered q12h or q24h for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1 2 and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC649128. panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo. panel 1: 2 participants receive placebo at a q24h regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC649128. panel 2 arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>004</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo. panel 2 arm 1: 2 participants receive placebo at a q12h regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC649128. panel 2 arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>006</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo. panel 2 arm 2: 2 participants receive placebo at a q24h regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC649128 panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>008</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo. panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>009</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo panel 4 arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo administered q12h or q24h for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1 2 and 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo.</intervention_name>
    <description>panel 1: 2 participants receive placebo at a q24h regimen.</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo.</intervention_name>
    <description>panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.</description>
    <arm_group_label>008</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC649128.</intervention_name>
    <description>panel 2, arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.</description>
    <arm_group_label>003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo.</intervention_name>
    <description>panel 2, arm 2: 2 participants receive placebo at a q24h regimen.</description>
    <arm_group_label>006</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>panel 4, arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.</description>
    <arm_group_label>009</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC649128</intervention_name>
    <description>panel 4, arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.</description>
    <arm_group_label>010</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC649128.</intervention_name>
    <description>panel 2, arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.</description>
    <arm_group_label>005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC649128</intervention_name>
    <description>panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.</description>
    <arm_group_label>007</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC649128.</intervention_name>
    <description>panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo.</intervention_name>
    <description>panel 2, arm 1: 2 participants receive placebo at a q12h regimen.</description>
    <arm_group_label>004</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented chronic (&gt; 6 months) genotype 1a or 1b Hepatitis C virus (HCV) infection

          -  Treatment-naive volunteer, meaning never received (Peg)IFN, RBV or any other approved
             or investigational treatment for chronic HCV infection (Panels 1, 2, 3 or 4) OR
             volunteer is a documented prior non-responder or relapser subject to previous
             treatment regimens (IFN/RBV or pegylated IFN/RBV) but has stopped this treatment at
             least 6 months before screening

          -  volunteer has never received a HCV polymerase inhibitor and HCV protease inhibitor
             treatment was stopped since at least one year (Panels 1, 2 or 3)

          -  Volunteer with HCV plasma RNA levels of &gt; 100,000 IU/mL at screening

          -  Body Mass Index of 18.0 to 35.0 kg/m2

          -  Healthy based on a medical evaluation including medical history, physical examination,
             blood tests, vital signs, and electrocardiogram.

        Exclusion Criteria:

          -  Evidence of liver cirrhosis

          -  Historical liver biopsy graded as liver cirrhosis or evidence for the presence of
             oesophageal varices or a transient elastography (Fibroscan) result of more than 14.6
             kPa within 2 years prior to screening

          -  Evidence of decompensated liver disease defined as prior history or current evidence
             of ascites, hepatic encephalopathy, bleeding oesophageal or gastric varices

          -  Evidence of renal dysfunction, documented by an estimated creatinine clearance below
             70 mL/min

          -  Evidence of any other cause of significant liver disease in addition to hepatitis C,
             this may include but is not limited to hepatitis B, drug- or alcohol-related
             cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, non-alcoholic
             steatohepatitis, or primary biliary cirrhosis

          -  Volunteer with diagnosed or suspected hepatocellular carcinoma

          -  Volunteer receiving or having received any treatment for HCV during the 6 months
             before screening

          -  Volunteer coinfected with Human Immunodeficiency Virus-1 (HIV-1) or HIV-2, or
             hepatitis A or B virus infection, or clinically active tuberculosis at study
             screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tibotec-Virco Virology BVBA Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Tibotec BVBA</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Zuidlaren</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krak√≥w</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2011</study_first_submitted>
  <study_first_submitted_qc>July 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2011</study_first_posted>
  <last_update_submitted>October 25, 2012</last_update_submitted>
  <last_update_submitted_qc>October 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TMC649128</keyword>
  <keyword>HCV</keyword>
  <keyword>TMC649128HPC1002</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Hep C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

